BRPI0511952A - receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 - Google Patents

receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14

Info

Publication number
BRPI0511952A
BRPI0511952A BRPI0511952-9A BRPI0511952A BRPI0511952A BR PI0511952 A BRPI0511952 A BR PI0511952A BR PI0511952 A BRPI0511952 A BR PI0511952A BR PI0511952 A BRPI0511952 A BR PI0511952A
Authority
BR
Brazil
Prior art keywords
induced
antibody
reducing
methods
treating
Prior art date
Application number
BRPI0511952-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Scott R Presnell
Steven K Burkhead
Steven D Levin
Rolf E Kuestner
Zeren Gao
Stephen R Jaspers
Janine Bilsborough
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0511952A publication Critical patent/BRPI0511952A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0511952-9A 2004-06-10 2005-06-10 receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 BRPI0511952A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57880504P 2004-06-10 2004-06-10
PCT/US2005/020521 WO2005123778A2 (en) 2004-06-10 2005-06-10 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
BRPI0511952A true BRPI0511952A (pt) 2008-01-29

Family

ID=35407029

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511952-9A BRPI0511952A (pt) 2004-06-10 2005-06-10 receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14

Country Status (11)

Country Link
US (4) US7910540B2 (cg-RX-API-DMAC7.html)
EP (1) EP1765865A2 (cg-RX-API-DMAC7.html)
JP (1) JP4903703B2 (cg-RX-API-DMAC7.html)
CN (1) CN101001871A (cg-RX-API-DMAC7.html)
AU (1) AU2005254998B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0511952A (cg-RX-API-DMAC7.html)
CA (1) CA2569867A1 (cg-RX-API-DMAC7.html)
IL (2) IL179356A (cg-RX-API-DMAC7.html)
MX (1) MXPA06014465A (cg-RX-API-DMAC7.html)
NO (1) NO20070153L (cg-RX-API-DMAC7.html)
WO (1) WO2005123778A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7324615B2 (en) * 2003-12-15 2008-01-29 Microchip Technology Incorporated Time signal receiver and decoder
BRPI0511952A (pt) * 2004-06-10 2008-01-29 Zymogenetics Inc receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14
CA2596986A1 (en) * 2005-02-14 2006-08-24 Wyeth Use of il-17f in diagnosis and therapy of airway inflammation
KR20070107703A (ko) * 2005-02-14 2007-11-07 와이어쓰 인터루킨-１７ｆ 항체 및 기타 ｉｌ-１７ｆ 신호전달안타고니스트 및 그의 용도
DK1931697T3 (da) 2005-09-28 2010-11-08 Zymogenetics Inc IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
WO2007117762A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
ATE467640T1 (de) * 2006-02-10 2010-05-15 Zymogenetics Inc Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
CA2646478A1 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
JP2010522564A (ja) 2007-03-26 2010-07-08 ザイモジェネティクス， インコーポレイテッド 可溶性ｉｌ−１７ｒａ／ｒｃ融合タンパク質および関連する方法
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
US8460647B2 (en) * 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
WO2008133684A1 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
AU2008266948B2 (en) * 2007-06-13 2012-08-23 Kirin-Amgen, Inc. IL-17 heteromeric receptor complex
WO2008156865A2 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
JP2010534664A (ja) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物
US20110300154A1 (en) * 2007-08-21 2011-12-08 Children's Medical Center Corporation Treatment of airway hyperreactivity
WO2009042162A2 (en) * 2007-09-25 2009-04-02 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
JP5886523B2 (ja) * 2008-01-09 2016-03-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2011096438A1 (ja) * 2010-02-03 2011-08-11 国立大学法人 東京大学 腸疾患の治療方法及び治療用医薬組成物
CN102188707B (zh) * 2011-02-25 2015-08-05 中国医学科学院基础医学研究所 Il-17抑制剂在制备治疗流感的药物中的用途
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
EP3456741B1 (en) 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
SG11202111175YA (en) * 2019-04-26 2021-11-29 Prolynx Llc Slow-release cytokine conjugates

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US20030100051A1 (en) * 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
WO1998049307A1 (en) 1997-05-01 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US7160985B2 (en) * 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US20030040471A1 (en) * 1998-04-29 2003-02-27 Watson James D. Compositions isolated from skin cells and methods for their use
US7247442B1 (en) * 1998-05-12 2007-07-24 Human Genome Sciences, Inc. Antibodies to HHPEN62 polypeptide
CA2332109A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
NZ508878A (en) * 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) * 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE508193T1 (de) * 1999-07-07 2011-05-15 Zymogenetics Inc Menschliches rezeptor für zytokine
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
ES2380812T3 (es) 1999-12-23 2012-05-18 Genentech, Inc. Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
US20040048249A1 (en) * 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
WO2001066722A1 (en) 2000-03-08 2001-09-13 Human Genome Sciences, Inc. Immune system-related polynucleotides, polypeptides, and antibodies
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
AU2001274920A1 (en) 2000-05-24 2001-12-03 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20040197306A1 (en) 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
AU2001271860A1 (en) 2000-07-06 2002-01-21 Zymogenetics Inc. Murine cytokine receptor
AU2002225714A1 (en) 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US6681210B2 (en) * 2001-09-04 2004-01-20 Andrew Jeffrey Kelly Modular service payroll system
US20040097447A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
HUE045709T2 (hu) 2003-07-08 2020-01-28 Genentech Inc Antagonista antitestek IL-17A/F heterológ polipeptidekhez
BRPI0511952A (pt) * 2004-06-10 2008-01-29 Zymogenetics Inc receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14
KR20070107703A (ko) 2005-02-14 2007-11-07 와이어쓰 인터루킨-１７ｆ 항체 및 기타 ｉｌ-１７ｆ 신호전달안타고니스트 및 그의 용도
DK1931697T3 (da) 2005-09-28 2010-11-08 Zymogenetics Inc IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
US20070249533A1 (en) * 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
ATE467640T1 (de) * 2006-02-10 2010-05-15 Zymogenetics Inc Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
JP2010522564A (ja) * 2007-03-26 2010-07-08 ザイモジェネティクス， インコーポレイテッド 可溶性ｉｌ−１７ｒａ／ｒｃ融合タンパク質および関連する方法

Also Published As

Publication number Publication date
US7910540B2 (en) 2011-03-22
IL208859A0 (en) 2011-01-31
CN101001871A (zh) 2007-07-18
JP4903703B2 (ja) 2012-03-28
CA2569867A1 (en) 2005-12-29
IL208859A (en) 2013-01-31
US20070048826A1 (en) 2007-03-01
WO2005123778A2 (en) 2005-12-29
AU2005254998A1 (en) 2005-12-29
NO20070153L (no) 2007-03-09
IL179356A (en) 2011-07-31
IL179356A0 (en) 2007-03-08
US8268773B2 (en) 2012-09-18
US20110177083A1 (en) 2011-07-21
US20070048257A1 (en) 2007-03-01
EP1765865A2 (en) 2007-03-28
AU2005254998B2 (en) 2011-10-27
US20060002925A1 (en) 2006-01-05
WO2005123778A3 (en) 2006-02-09
MXPA06014465A (es) 2007-05-16
JP2008509227A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
BRPI0511952A (pt) receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14
BRPI0408705A (pt) método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
Puxeddu et al. Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria
IL192950A0 (en) Soluble il-17rcx4 and methods of using in inflammation
NO20072602L (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
BRPI0719430B8 (pt) molécula de anticorpo isolada, composição, uso de uma molécula de anticorpo ou de uma composição, e, molécula de ácido nucleico isolado
MX2021009087A (es) Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
BR112012007365A2 (pt) proteínas de ligação à il-1
NO20090224L (no) Anti-IL-6 monoklonale antistoffer og anvendelser derav
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008133684A8 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
BRPI0908312A2 (pt) '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
MX2009009379A (es) Metodos y composiciones para tratar enfermedades tumorales.
AR059604A1 (es) Anticuerpos contra il- 22 humana y usos para los mismos
EA201590631A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
WO2009082624A3 (en) Antagonists of il-17a, il-17f, and il-23 and methods of using the same
NO20056236L (no) Behandling med anti-VEGF-antistoffer
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
RU2008126932A (ru) Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
Bonnin et al. Placental source for 5-HT that tunes fetal brain development
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
BRPI0416544A (pt) proteìna de ligação de gag

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.